|Bid||6.75 x 1300|
|Ask||7.17 x 900|
|Day's Range||6.71 - 7.10|
|52 Week Range||6.68 - 26.50|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug. 04, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.00|
BOSTON, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced it will present preclinical data for its anti-VISTA (V-domain Ig suppressor of T cell activation) product candidate, SNS-101, during the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held in Washington, D.C. from November 10 - 14, 2021. These data are the f
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Sensei Biotherapeutics, Inc. (SNSE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.